IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) concerning possible violations of federal securities laws.
If you purchased shares of Stryker and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation concerns whether Stryker and certain of its officers and/or directors violated federal securities laws. On August 23, 2017, the Company announced that it informed the Food and Drug Administration (“FDA”) of a voluntary product recall involving specific lots of its Oral Care products distributed between July 2015 and August 2017. Stryker’s recall followed a warning letter from the FDA received on July 17, 2017, which described a potential for cross-contamination of Oral Care products manufactured by a third party on equipment shared with non-pharmaceutical products. After receiving reports of minor irritation and allergic reaction, the Company discontinued its business relationship with the third-party supplier. Based on the estimated impact of the foregoing issues on sales and operating income, Stryker advised investors that the Company now expects full-year organic sales growth and adjusted net earnings per diluted share to be at the lower end of its previously stated ranges of 6.5% to 7.0% and $6.45 to $6.55, respectively. When this news was announced, shares of Stryker fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.